Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | DGKA | P23743 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
| ▸ | CASP2 | P42575 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 3/20 | 0.36 |
| ▸ | ICMT | O60725 | 1/20 | 0.36 |
| ▸ | ALB | P02768 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL889280 | 0.89 | KDM4E (0.38) | SMN1; SMN2DNM1L3MBTL1DGKAMAPT | |
| SCHEMBL889193 | 0.86 | DNM1 (0.49) | DNM1L3MBTL1DGKAMAPTFAAH | |
| SCHEMBL889191 | 0.86 | DNM1 (0.49) | DNM1FAAHCASP2CNR1ICMT | |
| SCHEMBL6123695 | 0.81 | MAPT (0.43) | SMN1; SMN2L3MBTL1DGKAMAPTEPHX2 | |
| SCHEMBL889147 | 0.81 | DGKA (0.52) | DNM1DGKAFAAHGAA | |
| SCHEMBL889199 | 0.81 | DNM1 (0.51) | DNM1FAAHCASP2CNR1ICMT | |
| SCHEMBL12120246 | 0.80 | DNM1 (0.48) | DNM1DGKAMAPTFAAH | |
| SCHEMBL17426965 | 0.80 | DNM1 (0.56) | DNM1L3MBTL1DGKAMAPTTSHR | |
| SCHEMBL17426970 | 0.80 | DNM1 (0.44) | DNM1L3MBTL1DGKAMAPTFAAH | |
| SCHEMBL17615499 | 0.80 | NAAA (0.47) | DNM1FAAHCASP2CNR1ICMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009222-A1 | MODULATION OF THE IMMUNE RESPONSE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009222-A1 | MODULATION OF THE IMMUNE RESPONSE | FCGRT, MYD88, C3AR1 | SMN1; SMN2 4845/4885DNM1 4279/4885L3MBTL1 4828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.